Abstract
Valproate-induced hyperammonemic encephalopathy is an unusual but serious adverse effect that is usually characterized by the acute onset of impaired consciousness, focal neurological symptoms and increased seizure frequency. It has been reported to occur at therapeutic valproate levels. We report a patient who developed valproate-induced hyperammonemic encephalopathy after a short treatment with valproate and was successfully treated with levocarnitine. We discuss this patient and review the literature regarding the use of levocarnitine in similar patients.
| Original language | English |
|---|---|
| Pages (from-to) | 690-691 |
| Number of pages | 2 |
| Journal | Journal of Clinical Neuroscience |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Encephalopathy
- Hyperammonemia
- Levocarnitine
- Valproic acid
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
- Physiology (medical)
- Medicine(all)
Cite this
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine. / Rigamonti, Andrea; Lauria, Giuseppe; Grimod, Gianluca; Bianchi, Graziella; Salmaggi, Andrea.
In: Journal of Clinical Neuroscience, Vol. 21, No. 4, 2014, p. 690-691.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine
AU - Rigamonti, Andrea
AU - Lauria, Giuseppe
AU - Grimod, Gianluca
AU - Bianchi, Graziella
AU - Salmaggi, Andrea
PY - 2014
Y1 - 2014
N2 - Valproate-induced hyperammonemic encephalopathy is an unusual but serious adverse effect that is usually characterized by the acute onset of impaired consciousness, focal neurological symptoms and increased seizure frequency. It has been reported to occur at therapeutic valproate levels. We report a patient who developed valproate-induced hyperammonemic encephalopathy after a short treatment with valproate and was successfully treated with levocarnitine. We discuss this patient and review the literature regarding the use of levocarnitine in similar patients.
AB - Valproate-induced hyperammonemic encephalopathy is an unusual but serious adverse effect that is usually characterized by the acute onset of impaired consciousness, focal neurological symptoms and increased seizure frequency. It has been reported to occur at therapeutic valproate levels. We report a patient who developed valproate-induced hyperammonemic encephalopathy after a short treatment with valproate and was successfully treated with levocarnitine. We discuss this patient and review the literature regarding the use of levocarnitine in similar patients.
KW - Encephalopathy
KW - Hyperammonemia
KW - Levocarnitine
KW - Valproic acid
UR - http://www.scopus.com/inward/record.url?scp=84896080454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896080454&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2013.04.033
DO - 10.1016/j.jocn.2013.04.033
M3 - Article
C2 - 24119342
AN - SCOPUS:84896080454
VL - 21
SP - 690
EP - 691
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
SN - 0967-5868
IS - 4
ER -